| DELMER, Alain |
IDA53, NCT03734198: Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with P53 Dysfunction |
|
|
| Active, not recruiting | 2 | 29 | Europe | Ibrutinib, Ibrutinib treatment, Daratumumab, Daratumumab perfusion | French Innovative Leukemia Organisation, Janssen, LP | Relapsed or Refractory Chronic Lymphocytic Leukemia | 06/23 | 12/25 | | |
NCT01976182: Prospective, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (Methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia |
|
|
| Active, not recruiting | 2 | 166 | Europe | Methotrexate, Cyclophosphamide | Rennes University Hospital | Large Granular Lymphocytes Leukemia | 02/24 | 05/27 | | |
COVID19_LLC-MW, NCT04391946: Observatory of Patients With Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenstrom Disease Infected With COVID-19 |
|
|
| Completed | N/A | 162 | Europe | Data registry | French Innovative Leukemia Organisation, Institut de cancérologie Strasbourg Europe | Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma or Waldenstrom Disease | 03/22 | 03/23 | | |
| Cadiot, Guillaume |
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Active, not recruiting | 3 | 160 | Europe, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis, Ulcerative Colitis Chronic | 08/24 | 09/25 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 01/30 | | |
| Active, not recruiting | 2 | 140 | Europe | LV5FU2, Streptozocin, Capecitabine, Temozolomide, Bevacizumab | Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France | Pancreatic Cancer | 12/28 | 12/28 | | |
NCT03622333: Clinic, Pathologic and Genetic Characterization of Patients With Familial Carcinoid Tumors (Study From the GTE, Groupe d'étude Des Tumeurs Endocrines) |
|
|
| Recruiting | N/A | 60 | Europe | Research of constitutional genetic alterations | CHU de Reims | Small Intestinal Carcinoid Tumors | 05/22 | 11/22 | | |
SAPHIR, NCT05598684: : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory Diseases |
|
|
| Recruiting | N/A | 600 | Europe, RoW | | Fresenius Kabi, France | Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis | 09/25 | 12/25 | | |
| BOUCHE, Olivier |
GASTFOX, NCT03006432: PHASE III RANDOMISED TRIAL TO EVALUATE FOLFOX WITH OR WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY FOR LOCALLY ADVANCED OR METASTATIC OESOPHAGO-GASTRIC CARCINOMA |
|
|
| Active, not recruiting | 3 | 507 | Europe, RoW | Oxaliplatin, 5Fluorouracil bolus, 5Fluorouracil continu, Docetaxel, Folinic Acid | Federation Francophone de Cancerologie Digestive, UNICANCER, GERCOR - Multidisciplinary Oncology Cooperative Group | OESOPHAGO-GASTRIC CARCINOMA | 12/25 | 12/25 | | |
ADAGE, NCT02355379: Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over |
|
|
| Recruiting | 3 | 774 | Europe | LV5FU2 or capectitabine, FOLFOX4 or XELOX, Observation, LV5FU2 or capecitabine | Federation Francophone de Cancerologie Digestive | Colonic Adenocarcinoma | 12/24 | 08/25 | | |
OSCAR, NCT02885753: Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver |
|
|
| Recruiting | 3 | 348 | Europe | Oxaliplatin intravenous, Oxaliplatin IV, 5 FU bolus, 5 FU, Folinic acid, Folinic Acid IV, Oxaliplatin intra-arteriel, Oxaliplatin IA, Panitumumab, Pani, Bevacizumab, Beva, 5 FU continuous, Irinotecan, IRI | Federation Francophone de Cancerologie Digestive | Colorectal Neoplasms | 09/25 | 09/27 | | |
ImadGist, NCT02260505: Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) |
|
|
| Completed | 3 | 136 | Europe | Imatinib maintenance, Glivec, Imatinib mésilate | Centre Leon Berard | Gastrointestinal Stromal Tumors, Resected Gastrointestinal Stromal Tumors, Non-metastatic, High Risk of Recurrence, KIT Gene Mutation | 12/23 | 12/23 | | |
REPROGRAM-02, NCT05462613: Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer |
|
|
| Recruiting | 2/3 | 446 | Europe | quality of life questionnaires, Blood sample, Regorafenib, Metronomic chemotherapies, Aspirin, Bevacizumab, FOLFIRI or FOLFOX | Centre Hospitalier Universitaire de Besancon | Metastatic Colorectal Cancer | 11/29 | 11/30 | | |
| Active, not recruiting | 2 | 99 | Europe | MPDL3280A, atezolizumab, mDCF, modified docetaxel, cisplatin, and fluorouracil | GERCOR - Multidisciplinary Oncology Cooperative Group, Roche Pharma AG | Anal Cancer | 02/23 | 12/24 | | |
NCT04894123: Cardiovascular Events From Trifluridine/Tipiracil +/- Oxaliplatin in Colorectal/Oesogastric Adenocarcinoma Patients |
|
|
| Terminated | 2 | 1 | Europe | Trifluridine/Tipiracil, Lonsurf, Oxaliplatin, Eloxatin | GERCOR - Multidisciplinary Oncology Cooperative Group, Servier | Colorectal Adenocarcinoma, Oesogastric | 02/23 | 02/23 | | |
| Completed | 2 | 77 | Europe | DONEPEZIL, PLACEBO | University Hospital, Clermont-Ferrand, Federation Francophone de Cancerologie Digestive | Digestive Oncology, Supportive Care | 01/24 | 01/24 | | |
LENVAGIST, NCT04193553: Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure |
|
|
| Completed | 2 | 77 | Europe | Lenvatinib, Placebo, Best supportive care | Centre Leon Berard | Gastro Intestinal Stromal Tumour | 01/24 | 04/24 | | |
MAZEPPA, NCT04348045: Personalized Maintenance Therapy for m-PDAC Using Olaparib or Selumetinib + Durvalumab, Based on BRCAness and KRAS Status. |
|
|
| Active, not recruiting | 2 | 307 | Europe | Arm A - Olaparib, AZD-2281, ARM B - durvalumab plus selumetinib, MEDI-4736 plus AZD-6244, ARM C FOLFIRI, folinic acid, fluorouracil, and irinotecan | GERCOR - Multidisciplinary Oncology Cooperative Group, AstraZeneca | Metastatic Pancreatic Adenocarcinoma | 07/23 | 12/24 | | |
CLavSyn, NCT03117972: Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels |
|
|
| Active, not recruiting | 2 | 177 | Europe | FOLFOXIRI, Irinotecan, Oxaliplatin, Leucovorin, 5-Fluorouracil, FOLFOX, FOLFIRI, Ironotecan, Bevacizumab, LV5FU2, Capecitabine | Centre Hospitalier Universitaire de Besancon | Metastatic Colorectal Cancer | 12/24 | 12/25 | | |
| Active, not recruiting | 2 | 176 | Europe | Trifluridine/Tipiracil, Lonsurf | GERCOR - Multidisciplinary Oncology Cooperative Group | Metastatic Colorectal Cancer | 11/23 | 11/24 | | |
TEDOPAM, NCT03806309: Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma |
|
|
| Recruiting | 2 | 106 | Europe | FOLFIRI, Leucovorin (Folinic Acid), Fluorouracil, Irinotecan, OSE2101, Tedopi | GERCOR - Multidisciplinary Oncology Cooperative Group, OSE Immunotherapeutics | Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer, Metastatic Cancer | 12/23 | 12/24 | | |
ALIX, NCT03974854: Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic Adenocarcinoma |
|
|
| Terminated | 2 | 25 | Europe | XELOXIRI-3, Capecitabine, Oxaliplatine, Irinotecan, Gemcitabine | Centre Hospitalier Universitaire de Besancon | Metastatic Pancreatic Adenocarcinoma | 08/23 | 02/24 | | |
BIG, NCT06253611: First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer |
|
|
| Recruiting | 2 | 120 | Europe | Nivolumab, Opdivo, FOLFOX regimen, Leucovorin, fluorouracil, and oxaliplatin, EXL01 | GERCOR - Multidisciplinary Oncology Cooperative Group | Gastric Cancer | 03/26 | 03/29 | | |
INTERACT-ION, NCT04719988: Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma. |
|
|
| Active, not recruiting | 2 | 55 | Europe | Blood sample collection, Biopsy | Centre Hospitalier Universitaire de Besancon, Boehringer Ingelheim | Squamous Cell Carcinoma of the Anus Stage III | 07/24 | 07/26 | | |
| Suspended | 2 | 80 | Europe | Riluzole, Placebo Oral Tablet | UNICANCER | Oxaliplatin-induced Peripheral Neuropathy | 03/25 | 03/25 | | |
CARE, NCT06425133: Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers |
|
|
| Not yet recruiting | 2 | 174 | Europe | Blood sample, Quality of life questionnaires, Biopsy, Regorafenib, Regorafenib + metronomic chemotherapy | Centre Hospitalier Universitaire de Besancon, Groupement Interrégional de Recherche Clinique et d'Innovation | Metastatic Colorectal Cancer | 09/27 | 09/28 | | |
POCHI, NCT04262687: Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate |
|
|
| Recruiting | 2 | 55 | Europe | Capecitabine, Oxaliplatin, Bevacizumab, Pembrolizumab | Federation Francophone de Cancerologie Digestive | Colorectal Cancer Metastatic, High Immune Infiltrate, Microsatellite Stable | 09/24 | 09/24 | | |
SOREGATT, NCT04450836: Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 340 | Europe | Regorafenib then Trifluridine/Tipiracil, STIVARGA, LONSURF, Trifluridine/Tipiracil then Regorafenib | UNICANCER | Metastatic Colorectal Cancer | 11/24 | 05/28 | | |
GIST-TEN, NCT05009927: Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten) |
|
|
| Recruiting | 2 | 50 | Europe | Imatinib tablets, Glivec | Centre Leon Berard | Metastatic Gastrointestinal Stromal Tumor (GIST), C-KIT Mutation, Advanced Gastrointestinal Stromal Tumor (GIST) | 01/25 | 01/27 | | |
ATEZOGIST, NCT05152472: A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments |
|
|
| Recruiting | 2 | 110 | Europe | Atezolizumab 1200 mg, Tecentriq®, Imatinib 400 MG, Glivec® | Centre Leon Berard | Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST), Metastatic Gastrointestinal Stromal Tumor | 10/27 | 10/27 | | |
LOGICAN, NCT05476796: Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer |
|
|
| Recruiting | 2 | 118 | Europe | Trifluridine/Tipiracil, Lonsurf, Oxaliplatin, FOLFOX regimen, Nivolumab, OPDIVO | UNICANCER, Servier | Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 01/26 | 01/27 | | |
NIPISAFE, NCT04730544: Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. |
|
|
| Recruiting | 2 | 96 | Europe | Nivolumab 480mg + Ipilimumab, Opdivo, Yervoy, Nivolumab 240 mg + Ipilimumab | GERCOR - Multidisciplinary Oncology Cooperative Group, Bristol-Myers Squibb | Colorectal Cancer Metastatic, MSI-H Colorectal Cancer | 04/27 | 04/28 | | |
LAP-NET1, NCT05546853: Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma |
|
|
| Recruiting | 1 | 52 | Europe | NP137, Oxaliplatin, Irinotecan, Calcium levofolinate, 5 FU | University Hospital, Grenoble, NETRIS Pharma | Pancreatic Ductal Adenocarcinoma | 03/26 | 03/27 | | |
| Recruiting | N/A | 402 | Europe | treatment for ampullary adenocarcinoma, no other intervention name to add | Federation Francophone de Cancerologie Digestive | Ampullary Adenocarcinoma | 12/22 | 12/22 | | |
| Completed | N/A | 56 | Europe | Adipose tissue sampling during surgery and urine sampling | CHU de Reims | Carcinoma, Pancreatic Ductal | 02/23 | 05/23 | | |
| Recruiting | N/A | 330 | Europe | Blood sampling to build population pharmacokinetics model | UNICANCER | Digestive Cancer, Metastatic Colorectal Cancer, Hepatocellular Carcinoma, GIST, Neuroendocrine Tumors | 08/26 | 06/27 | | |
COBRAF, NCT05639413: A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer |
|
|
| Recruiting | N/A | 400 | Europe | Collection of blood samples | UNICANCER, Pierre Fabre Medicament | Metastatic Colorectal Cancer, BRAF V600E Mutation Positive | 07/27 | 07/28 | | |
| Recruiting | N/A | 4050 | Europe | | GERCOR - Multidisciplinary Oncology Cooperative Group | Pancreatic Adenocarcinoma | 12/30 | 12/31 | | |
| Active, not recruiting | N/A | 25 | Europe | Patient treated by Avapritinib in real life | Centre Leon Berard, Blueprint Medicines Corporation | GIST, GIST, Malignant, PDGFR-Alpha D842V | 04/24 | 12/24 | | |
| HIMBERLIN, Chantal |
| Recruiting | 3 | 124 | Europe | EPREX, Epoetin alfa | Groupe Francophone des Myelodysplasies | Myelodysplastic Syndromes | 05/22 | 05/24 | | |
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy |
|
|
| Active, not recruiting | 3 | 777 | Europe, RoW | Gilteritinib, ASP2215, Midostaurin, Rydapt | Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc. | Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 | 12/24 | 06/33 | | |
BIG-1, NCT02416388: Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR |
|
|
| Recruiting | 2/3 | 3100 | Europe | Idarubicin, Daunorubicin, HD Cytarabine, Cyclosporine, Methotrexate, Mycophenolic acid (MPA), vosaroxin, ID cytarabine, Dexamethasone, Venetoclax | University Hospital, Angers | Acute Myeloid Leukemia (AML) | 07/25 | 01/32 | | |
| Completed | 2 | 42 | Europe | CPX-351 | French Innovative Leukemia Organisation, Acute Leukemia French Association, French Intergroup of Myeloproliferative syndromes | Acute Myeloid Leukemia, Myeloproliferative Syndrome | 10/23 | 12/23 | | |
LAMSA2020, NCT04968015: Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission |
|
|
| Active, not recruiting | 2 | 134 | Europe | Cytarabine-Venetoclax Association, Cytarabine-Idarubicin Association | French Innovative Leukemia Organisation | Acute Myeloid Leukemia | 08/25 | 01/29 | | |
AGORA-1, NCT05199051: A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD Relapse/Refractory (R/R) AML |
|
|
| Recruiting | 2 | 50 | Europe | Gemtuzumab ozogamicine - Cytarabine - Gilteritinib, Mylotarg - Aracytine - Xospata | Centre Antoine Lacassagne, Acute Leukemia French Association | AML | 03/27 | 03/27 | | |
VENAZA, NCT06263387: Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine |
|
|
| Recruiting | N/A | 230 | Europe | | French Innovative Leukemia Organisation, Acute Leukemia French Association | AML, Adult | 12/24 | 03/25 | | |
| PLANTIER, Isabelle |
BIG-1, NCT02416388: Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR |
|
|
| Recruiting | 2/3 | 3100 | Europe | Idarubicin, Daunorubicin, HD Cytarabine, Cyclosporine, Methotrexate, Mycophenolic acid (MPA), vosaroxin, ID cytarabine, Dexamethasone, Venetoclax | University Hospital, Angers | Acute Myeloid Leukemia (AML) | 07/25 | 01/32 | | |
ALFA2101, NCT05260528: CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics |
|
|
| Recruiting | 2 | 210 | Europe | Cytarabine and Idarubicin, CPX-315 | Centre Hospitalier Universitaire de Nice, Jazz Pharmaceuticals, Acute Leukemia French Association | Acute Myeloid Leukemia | 10/27 | 10/27 | | |
ALFAPPP, NCT04777916: Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML) |
|
|
| Recruiting | N/A | 2500 | Europe | | Acute Leukemia French Association | Acute Myeloid Leukemia (AML) | 04/32 | 04/46 | | |
| GRANGE, Florent |
SPINO-RT, NCT06692556: Randomized Comparative Multicenter Phase III Study of a Strategy Integrating Adjuvant Radiation Therapy Versus Strategy Based on Monitoring in the Treatment of Carcinomas Spinocellular With High Risk of Recurrence |
|
|
| Not yet recruiting | 3 | 266 | Europe | Adjuvant radiotherapy | Centre Leon Berard | Cutaneous Squamous Cell Carcinoma (CSCC) | 06/29 | 06/29 | | |
| Active, not recruiting | 3 | 407 | Europe, US, RoW | IO102-IO103, Pembrolizumab | IO Biotech, Syneos Health, Merck Sharp & Dohme LLC | Metastatic Melanoma, Unresectable Melanoma | 07/25 | 09/27 | | |
| Active, not recruiting | 2 | 271 | Europe | Nivolumab + Ipilimumab, Encorafenib + Binimetinib | European Organisation for Research and Treatment of Cancer - EORTC | Unresectable Stage III Melanoma, Stage IV Melanoma | 10/23 | 01/27 | | |
| Recruiting | N/A | 9000 | Europe | | University Hospital, Lille | Adnexal Tumor of Skin, Merkel Cell Carcinoma, Advanced Basal Cell Carcinoma Requiring Systemic Treatment | 12/25 | 12/25 | | |
| Bouché, Olivier |
NEXT-REGIRI, NCT03829462: Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients |
|
|
| Active, not recruiting | 3 | 66 | Europe | Regorafenib, Irinotecan | Institut du Cancer de Montpellier - Val d'Aurelle | Metastatic Colorectal Cancer (mCRC) | 09/24 | 09/25 | | |
| Not yet recruiting | 3 | 244 | NA | Avastin, 25 Mg/mL Intravenous Solution, Experimental group, Control group | University Hospital, Tours, CHU DE BESANCON, Gustave Roussy, Cancer Campus, Grand Paris, CHU de Clermont-Ferrand, CHU de Reims, CHU de Brest, AP-HP, Hôpital Pitié- Salpétrière, CHU de Rouen, Poitiers University Hospital, Institut Paoli-Calmettes, Rennes University Hospital, University Hospital, Toulouse, AP-HP, Hôpital Saint-Louis, HCL Hôpital Edouard Hériot, Centre Hospitalier Universitaire Dijon, Nantes University Hospital, Centre Hospitalier Universitaire, Amiens, Hôpital Privé Jean Mermoz, AP-HP, Hôpital Henri Mondor, AP-HP, Hôpital Paul Brousse, CHG de St-Malo, Polyclinique de Blois, University Hospital, Caen, CHU de Nancy | Unresectable Metastatic Colorectal Cancer | 10/28 | 10/29 | | |
APACaPOp, NCT03400072: Adapted Physical Activity in Patients With Resected Pancreatic Cancer ( PRODIGE-56 Study): a National Multicenter Randomized Controlled Phase II Trial |
|
|
| Recruiting | 2 | 252 | Europe | Unsupervised APA program, Supervised APA program | Centre Hospitalier Universitaire de Besancon, GERCOR - Multidisciplinary Oncology Cooperative Group | Pancreas Cancer, Quality of Life | 02/22 | 08/24 | | |
| DUROT, Eric |
MorningLyte, NCT06284122: Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 |
|
|
| Recruiting | 3 | 790 | Europe | Mosunetuzumab, Lenalidomide, Rituximab, Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristin, Prednisone, Bendamustin | The Lymphoma Academic Research Organisation, Lymphoma Study Association, Swiss Group for Clinical Cancer Research, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Follicular Lymphoma | 11/28 | 04/34 | | |
| Active, not recruiting | 2 | 74 | Europe | Pixantrone, Pixuvri, Ifosfamide, Holoxan, Etoposide, Vepeside, Rituximab, Mabthera, Transplant | The Lymphoma Academic Research Organisation | Aggressive Non-Hodgkin Lymphoma | 06/19 | 03/25 | | |
GLOASIS, NCT06558604: A Phase II Study Evaluating Glofitamab in Combination With Venetoclax Plus Zanubrutinib or Venetoclax Alone in Subjects With Untreated or Relapsed/Refractory High-risk Mantle-cell Lymphoma |
|
|
| Not yet recruiting | 2 | 100 | Europe | Obinutuzumab, Glofitamab, Venetoclax Oral Product, Zanubrutinib Oral Capsule | The Lymphoma Academic Research Organisation, BeiGene, Hoffmann-La Roche | Lymphoma, Mantle-Cell | 05/28 | 03/32 | | |
| Recruiting | 2 | 56 | Europe | Lacutamab, Gemcitabine, Oxaliplatine | The Lymphoma Academic Research Organisation, Innate Pharma | Peripheral T Cell Lymphoma, Relapse/Recurrence | 01/25 | 01/27 | | |
|
OASIS-II, NCT04802590: Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma |
|
|
| Recruiting | 2 | 194 | Europe | Ibrutinib 560 mg, Venetoclax 10 MG Oral Tablet [Venclexta], Venetoclax 50 MG Oral Tablet [Venclexta], Venetoclax 100 MG Oral Tablet [Venclexta] | The Lymphoma Academic Research Organisation, Institute of Cancer Research, United Kingdom | Mantle Cell Lymphoma | 03/26 | 09/31 | | |
| Recruiting | N/A | 500 | Europe | | French Innovative Leukemia Organisation | Waldenstrom's Disease, Prognostic Index | 06/30 | 06/30 | | |
NCT04220970: Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry |
|
|
| Recruiting | N/A | 150 | Europe | BIA-ALCL | The Lymphoma Academic Research Organisation | Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL) | 06/32 | 06/32 | | |
| PERRENOT, Cyril |
FLUOCOL-1, NCT05168839: Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage |
|
|
| Recruiting | 3 | 1010 | Europe | FLUO+ : Intraoperative fluorescence angiography (IOFA) with indocyanine green (ICG). | Centre Hospitalier Universitaire de Besancon | Colorectal Cancer | 10/25 | 10/25 | | |
NCT04132986: Study of Absorbable Biosynthetic Meshes in Contaminated Ventral Hernia Repair |
|
|
| Recruiting | N/A | 200 | Europe | | University Hospital, Strasbourg, France | Ventral Hernia Repair | 06/23 | 06/23 | | |
| AMROUN, Koceila Lamine |
FLUOCOL-1, NCT05168839: Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage |
|
|
| Recruiting | 3 | 1010 | Europe | FLUO+ : Intraoperative fluorescence angiography (IOFA) with indocyanine green (ICG). | Centre Hospitalier Universitaire de Besancon | Colorectal Cancer | 10/25 | 10/25 | | |
